Sanofi (SNY) Q3 2026 earnings review
Sanofi raises its outlook, while vaccine sales fall
Sanofi's immunology blockbuster Dupixent and newly launched drugs carried the French drugmaker while its vaccine business shrank. Constant-currency sales grew 14% and profit per share excluding one-offs rose 20%, helped by flat research and overhead costs. Chief executive Belén Garijo raised the full-year outlook, though by our math the new plan points to sales growth slowing to about 3% in the fourth quarter.
| Net sales (constant currency) | €14,444M +14.3% from a year ago (+16.2% reported) |
|---|---|
| Business EPS (excluding one-offs) | €3.55 +19.6% at constant currency |
| Dupixent sales | €5,687M +34.8% at constant currency |
| Full-year 2026 outlook | Raised Sales up low-teens %, EPS up mid-teens % |
⚖️ Verdict: 🟢 Bullish
The story got better because Sanofi expanded its antibody alliance with Regeneron to develop four next-generation drugs, easing fears of a partner rift and taking a concrete step toward replacing Dupixent after 2031. One caution: US sales and gross margin again leaned on favourable rebate adjustments that management previously indicated would not repeat, while US orders for infant RSV vaccine Beyfortus dropped 39%.
The question now is whether the steep fourth-quarter slowdown implied by the full-year plan is typical management caution or a real drop as one-off US pricing tailwinds fade. If patient volume is driving the beat, fourth-quarter growth will top the implied 3% pace; if rebate true-ups carried the summer, growth will step down. Fourth-quarter results on January 28, 2027 will tell.
🐂 Bull Case
Regeneron Deal Adds Four Next-Generation Antibodies
Dupixent, Sanofi's flagship treatment for inflammatory diseases such as eczema and asthma, brings in 39% of group sales and loses its main US product patent in March 2031. Investors also worried about friction with Regeneron, the US biotech partner that co-developed the drug. Chief executive Belén Garijo addressed both issues directly: "In the third quarter, we accelerated Sanofi’s transformation by expanding our long-standing alliance with Regeneron, which opens up further opportunities in immunology."
Under the October agreement, the two partners will co-develop and split profits equally on four long-acting Regeneron antibodies targeting the same biological pathways as Dupixent. Sanofi will pay $1 billion upfront and up to $7 billion in milestones, while Regeneron gets an option to join Sanofi's asthma candidate lunsekimig after phase 3 trials.
The deal shows both companies can still work together on their core franchise, easing governance fears. However, it does not solve the 2031 patent cliff yet, because only one of the four antibodies is in phase 1 human trials today and the other three will not enter the clinic until 2027.
What to watch: phase 1 clinical data for the lead antibody REGN20423 and the start of human trials for the other three candidates in 2027. Early clinical success would show Sanofi can transition patients to longer-acting shots before generic copies of Dupixent arrive.
Dupixent and New Launches Keep Firing
Sanofi relies on Dupixent and a basket of 13 recently launched medicines to outgrow its older drugs before 2030. Both engines grew over 30% at constant exchange rates this quarter, pushing group sales up 14.3% to €14.4 billion. The French drugmaker also gained ground in rare diseases and China, where sales rose 2.6% after falling in the first half.
- Dupixent sales: €5.69 billion, up 34.8% at constant currency, topping €5 billion for a second consecutive quarter
- New pharma launches: €1.39 billion, up 31.4% at constant currency, led by hemophilia treatment ALTUVIIIO (€408 million, up 37.8%)
- Ayvakit (a rare blood disorder drug acquired with Blueprint): €203 million, up 46.0% reported and up 14.4% on a comparable market basis
- Rezurock (for transplant complications) and Sarclisa (for blood cancer): up 43.0% to €165 million and up 25.8% to €196 million
This matters because the launch basket now brings in 9.6% of group sales and is on pace to meet management's €5.2–5.3 billion full-year target without acquisition tailwinds. Furthermore, the US Food and Drug Administration approved a higher 50 mg dose of Ayvakit this quarter, and Sanofi launched three new rare-disease drugs in China.
What to watch: fourth-quarter phase 3 trial results for Sarclisa in newly diagnosed transplant-eligible multiple myeloma patients. A positive readout would open a larger front-line patient group in the US and keep the launch basket growing above 25%.
Flat Research and Overhead Costs Lifted Margins
Sanofi's profit excluding one-offs grew faster than sales because management kept a lid on operating budgets while high-margin specialty drugs grew. Business operating income rose 19.7% at constant currency to €5.43 billion, lifting the operating margin by 1.9 percentage points to 37.6% of sales. That expansion overcame a jump in profit-sharing payments to Regeneron and the end of Regeneron's research reimbursement.
- Business gross margin (profit left after manufacturing costs): 81.0% of sales, up 2.1 percentage points from a year ago
- Research and development (R&D) spending: €1.85 billion, down 0.1% at constant currency, falling 1.9 percentage points to 12.8% of sales
- Selling and general overhead: €2.31 billion, down 0.9% at constant currency, falling 2.4 percentage points to 16.0% of sales
- Regeneron alliance net expense: €2.40 billion, up 5.6 percentage points to 16.6% of sales as Dupixent profits grew and development repayments ended
R&D spending stayed flat "mainly reflecting past project terminations in Vaccines", while Amvuttra royalty income more than doubled to €296 million, cushioning the €282 million drop in Regeneron research repayments. What to watch: whether R&D as a share of sales rebounds in 2027 as four new Regeneron antibodies and phase 3 programs ramp up. If research spending stays suppressed, cost discipline could mask underinvestment in the pipeline.
🐻 Bear Case
US Pricing Adjustments Carry Part of the Beat
Sanofi presents its 14.3% sales growth and 81.0% gross margin as proof of underlying demand for specialty medicines. Last quarter, after a roughly €200 million benefit from US gross-to-net price adjustments (true-ups between list prices and the rebates paid to insurers and government programs), management indicated that this tailwind would not repeat later in the year.
Instead, rebate adjustments boosted the third quarter across multiple franchises. Sanofi said US Dupixent sales rose 40.2% in part from "an extended benefit from operational improvements which resulted in favourable gross-to-net price adjustments". Older diabetes insulins Lantus (up 35.0% in the US) and Toujeo (up 121.8% in the US) also surged "primarily driven by favourable gross-to-net price adjustments and supported by market share gains", alongside rival supply shortages.
The company did not disclose the euro size of this quarter's rebate tailwind, so outsiders cannot separate true patient volume growth from accounting true-ups on past rebates. Because these adjustments also lifted the 81.0% gross margin, both US revenue growth and profitability look stronger than repeatable patient demand.
What to watch: fourth-quarter US Dupixent and insulin growth rates, plus any quantification on the earnings call of the rebate benefit. A sharp slowdown once rebate adjustments normalize would confirm that third-quarter margins and US growth were flattered by temporary pricing items.
US Vaccine Demand Weakens Beyond Flu Timing
Vaccines are Sanofi's second-largest business, and management already cut its 2030 vaccine sales target last quarter. Total vaccine revenue fell 6.6% at constant currency to €3.19 billion in the third quarter. While that beat the company's warning of a low-to-mid-teens drop, the beat relied on newly acquired hepatitis B shot Heplisav-B, which pushed the polio, pertussis and booster line up 69.8% in the US.
Excluding that acquisition, core respiratory and pediatric vaccines struggled. Influenza and COVID-19 shots fell 18.8% to €1.26 billion as Northern Hemisphere deliveries shifted into the fourth quarter. More concerning, infant RSV preventative shot Beyfortus dropped 15.4% globally to €631 million and sank 39.3% in the US to €240 million, "including a lower central order from the Centers for Disease Control and Prevention".
Lower US government orders for Beyfortus and falling birthrates hurting childhood vaccines in China are demand issues, not calendar shifts. What to watch: fourth-quarter vaccine sales to see if delayed flu shipments fully make up the third-quarter drop. If full-year vaccine sales still decline, pressure on US immunization rates is hurting the franchise permanently.
Raised Outlook Still Points to a Slow Fourth Quarter
Sanofi beat its own third-quarter expectations and raised its full-year 2026 outlook to low-teens sales growth and mid-teens business EPS growth at constant exchange rates. However, through the first nine months of 2026, net sales have already grown 15.2% and business EPS has risen 21.3% at constant currency.
By our math, hitting the middle of the new full-year ranges (about 12% for sales and 15% for business EPS) leaves only about 3% constant-currency sales growth and an 11% drop in business EPS for the fourth quarter. That implied slowdown occurs even though delayed third-quarter flu vaccine shipments are supposed to land in the fourth quarter.
The third-quarter beat proves the previous full-year outlook was conservative, but the new outlook still bakes in a steep year-end deceleration as Sanofi laps last year's Blueprint acquisition and strong late-2025 Dupixent launches. What to watch: fourth-quarter constant-currency sales growth on January 28, 2027. A reading near 3% would mean the growth step-down is real rather than management caution.
Risks this quarter didn't answer
Three standing concerns around pipeline execution, deal discipline, and accounting adjustments remained unresolved in the third-quarter release.
- Late-stage pipeline execution: after several trial failures over the past year, lunsekimig posted positive phase 2 asthma data, but pivotal phase 3 readouts for nerve-disorder drug riliprubart and multiple sclerosis drug frexalimab do not arrive until 2027 and 2028.
- Acquisition discipline: Garijo said "Business development and M&A will be critical to complement this transformation" and "Our priority is to protect earnings through Dupixent’s loss of exclusivity"; how much Sanofi pays for its next commercial-stage target will test capital discipline.
- Gap between reported and adjusted profit: nine-month IFRS net income of €4.98 billion sits €4.04 billion below business net income due to €1.64 billion of acquisition amortisation, €1.02 billion of impairments, €648 million of restructuring, and €382 million of litigation charges.
👓 Other Themes
Cheplapharm Partnership Trims Older Medicines
In September, Sanofi agreed to transfer 20 mature medicines—including blood thinner Lovenox outside the US, which had €822 million in 2025 sales—and three factories to German partner Cheplapharm. In return, the French group will take a 26.4% equity stake in Cheplapharm when the deal closes between the first and third quarters of 2027, removing shrinking legacy drugs from top-line growth.
💲 Other KPIs
Free cash flow—cash left from operations after capital spending, restructuring, and small bolt-on deals—rose 9.2% from a year ago in the third quarter and 28.3% over the first nine months to €6.99 billion. That represents 22.6% of third-quarter sales, funding both capital spending of €1.51 billion year-to-date and dividend payments.
Net debt—total borrowings minus €5.97 billion of cash—dropped by €3.31 billion from June's €15.51 billion peak as third-quarter cash flow came in. Compared with the start of 2026, net debt is still up €1.21 billion because nine-month free cash flow was outweighed by the €4.92 billion dividend, the €1.65 billion Dynavax acquisition, and €1.01 billion of share buybacks.
The basic share count fell 1.5% from 1,218.1 million a year ago after the drugmaker completed its €1 billion share repurchase program in April 2026. Compared with the second quarter's 1,196.6 million shares, the count edged up slightly as no new buyback program was started, adding about 2 percentage points to year-over-year per-share profit growth.
🔮 Guidance
Raised. Management lifted its full-year constant-currency sales plan from around 10% to a low-teens percentage (about 12% at the middle of the range), with currency swings expected to trim reported sales by about 1%. By our math, after 15.2% growth in the first nine months, that leaves only about 2.9% growth for the fourth quarter against a tough 13.3% comparison a year ago. This is the second raise this year (+2 points in Q2, +2 points in Q3).
Raised. The company now expects profit per share excluding one-offs to grow by a mid-teens percentage at constant exchange rates (about 15% at the middle of the range), minus a roughly 1% currency drag. By our math, because nine-month business EPS is already up 21.3%, the plan implies an 11% fourth-quarter decline as development repayments from Regeneron remain near zero.
Unchanged. Sanofi still expects its full-year tax rate on business net income to sit around 21%, up from 19.9% in 2025 after pipeline write-offs earlier this year could not be deducted for tax purposes. The third-quarter rate was 20.4% and the nine-month rate sits at 21.1%, right in line with the full-year target.
❓ Key Questions
How much did US rebate adjustments add in Q3?
Last quarter management said the €200 million second-quarter gross-to-net pricing benefit would not repeat, yet favourable rebate adjustments boosted US Dupixent, Lantus, Toujeo, and gross margin in the third quarter. Without the euro figure, investors cannot judge underlying patient volume growth.
Why does the raised outlook imply 3% Q4 growth?
Nine-month sales are up 15.2% at constant currency, so a low-teens full-year plan points to roughly 3% growth in the fourth quarter by our math, even with delayed flu vaccine deliveries arriving. How much of that step-down is management caution versus real deceleration?
Why did CDC orders for Beyfortus drop in Q3?
US sales of infant RSV shot Beyfortus fell 39.3% on lower orders from the Centers for Disease Control and Prevention. Is that a timing shift into the fourth quarter, or is US demand eroding from competing maternal vaccines and policy changes?
How will Cheplapharm affect 2027 sales and earnings?
Sanofi is transferring 20 older drugs, including ex-US Lovenox (€822 million in 2025 sales), and three factories to Cheplapharm for a 26.4% stake in 2027. Management has not yet said how much revenue and operating profit will leave the consolidated accounts.
When will management present the full R&D review?
Chief executive Belén Garijo promised to share her enterprise strategy and pipeline review conclusions by the end of 2026, and noted that acquisitions will be critical to protect earnings after 2031. What deal size ceiling and therapeutic areas will govern those acquisitions?